Screening for ovarian cancer
Goswamy, R.K.; Campbell, S.; Chamberlain, J.
Iarc Scientific Publications 76: 305-309
1986
ISSN/ISBN: 0300-5038 PMID: 3552976 Document Number: 276479
Document emailed within 1 workday
Related Documents
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Quinn, M.A. 2001: Screening for ovarian cancer Australian Family Physician 30(6): 530-534
Jacobs, I.; Oram, D. 1988: Screening for ovarian cancer Biomedicine and PharmacoTherapy 42(9): 589-596
Amram-Benamran, M.-L.; Cochet, S.; Petignat, P.; Sappino, A.-P. 2010: Ovarian cancer screening: recommendations for clinical pratice Revue Medicale Suisse 6(250): 1062; 1064 1066-1068
Rampone, B.; Rampone, A.; Tirabasso, S.; Panariello, S.; Rampone, N. 2001: Ovarian cancer screening by transvaginal color Doppler ultrasonography Minerva Ginecologica 53(1 Suppl 1: 125-128
Yang, Z.-j.; Yang, G.; Jiang, Y.-m.; Ran, Y.-l.; Yang, Z.-h.; Zhang, W.; Zhang, J.-q.; Pan, Z.-m.; Li, L. 2007: Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens Zhonghua Fu Chan Ke Za Zhi 42(12): 834-839
Misawa, T.; Asai, M.; Higashide, K. 1997: How to decrease false-positive cases of ovarian cancer screening by transvaginal sonography Journal of Experimental and Clinical Cancer Research: Cr 16(2): 217-220
Foulkes, W.D.; Narod, S.A. 1995: Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing Clinical and Investigative Medicine. Medecine Clinique et Experimentale 18(6): 473-483
Popovska, S.; Ivanov, I.; Dineva, T.; Jordanov, A.; Kovacheva, K.; Kamburova, Z.; Tomov, S.; Ivanova, V.; Boneva, I.; Mateva, S. 2014: Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer Akusherstvo i Ginekologiia 53(4): 21-28
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
1993: Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117--December 1992 International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 41(3): 321-323
Paskett, E.D.; Tatum, C.M.; D'Agostino, R.; Rushing, J.; Velez, R.; Michielutte, R.; Dignan, M. 1999: Community-based interventions to improve breast and cervical cancer screening: results of the Forsyth County Cancer Screening (FoCaS) Project Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 8(5): 453-459
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Chou, Y-Ching.; Chen, Y-Jen.; Lai, C-Ru.; Wang, P-Hui.; Hsin-Chan; Yuan, C-Chung. 2006: Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis European Journal of Obstetrics Gynecology and Reproductive Biology 124(1): 101-105
Ivanov, S.; Batashki, I. 2008: Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer Akusherstvo i Ginekologiia 47(5): 9-11
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Milsom, I.; Odlind, V. 2008: Oral contraceptives give long-lasting protection against ovarian cancer. use of oral contraceptives can explain reduced incidence of ovarian cancer in Sweden Lakartidningen 105(10): 715-716